For research use only. Not for therapeutic Use.
Dihydrexidine hydrochloride (DAR-0100 hydrochloride) is a high potent, selective and full efficacy D1-like dopamine receptor (D1/D5) agonist, with an IC50 of 10 nM for D1 receptor. Dihydrexidine hydrochloride exhibits potent antiparkinsonian activity[1][2][3][4]. Dihydrexidine hydrochloride can stimulate YAP phosphorylation[5].
Dihydrexidine (DAR-0100) strongly increased YAP phosphorylation in U2OS cells[5].
Dihydrexidine hydrochloride has poor oral bioavailability and a relatively short half-life of 1 to 2 h[3].
Dihydrexidine hydrochloride (3 mg/kg; i.p.) produces prominent dopamine D1 receptor agonist effects in vivo[4].
Catalog Number | I026138 |
CAS Number | 137417-08-4 |
Molecular Formula | C17H18ClNO2 |
Purity | ≥95% |
Reference | [1]. Lovenberg TW, et al. Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist. Eur J Pharmacol. 1989 Jul 4;166(1):111-3. [2]. Mottola DM, et al. Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist. J Pharmacol Exp Ther. 1992 Jul;262(1):383-93. [3]. Salmi P,et al. Dihydrexidine–the first full dopamine D1 receptor agonist. CNS Drug Rev. 2004 Fall;10(3):230-42. [4]. Gleason, S. D., et al. Effects of dopamine D1 receptor agonists in rats trained to discriminate dihydrexidine. Psychopharmacology, 2006;186(1), 25–31. [5]. Yu FX, et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 2012;150(4):780-791. |